Sun Pharmaceuticals on Tuesday has launched specialty ophthalmology therapy, CEQUA, in India for patients who have Dry Eye Disease (DED) with inflammation, a commonly occurring condition.
In company’s press statement, CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology.
Kirti Ganorkar, CEO – India Business, Sun Pharma, said in a statement that “Current treatment options for Dry Eye Disease have limitations and hence a strong unmet need exists in this space. We are excited to introduce CEQUA as a new treatment option for Dry Eye Disease in India. This is an important milestone for Sun Pharma as we bring one of our key global specialty products to India.”
The company has launched the therapy in October 2019 in US market after extensive clinical studies. The prevalence of DED is higher in India compared to global prevalence. It is projected that the prevalence of DED is likely to increase to 45% in India’s urban population by 2030.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
